A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease

Trial Profile

A Phase II, Double-blind, Randomised, Placebo-controlled, Parallel Group Pilot Study to Evaluate the Safety and Efficacy of FFP104 in the Treatment of Subjects With Moderate to Severely Active Crohn's Disease

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Oct 2017

At a glance

  • Drugs FFP 104 (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Sponsors FF Pharma
  • Most Recent Events

    • 18 Oct 2017 The trial is completed in Netherlands according to European Clinical Trials Database record.
    • 14 Sep 2017 The trial is completed in Belgium.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top